Subscribe to our Telegram channel to get a daily dose of business and lifestyle news from NHA – News Hub Asia!
“We are delighted to have Dr. Adams join our team as we continue to build the new Cordis,” said CEO Shar Matin. “His depth of expertise in the treatment of both complex coronary and peripheral vascular disease will play a vital role in furthering our mission to improve patient care at pace with cost-effective, differentiated solutions that build on our legacy of innovation.”
Dr. Adams comes to Cordis with a distinguished combination of clinical practice, medical research, and product development experience. He is globally recognized for his expertise in the treatment of peripheral vascular disease in patients with critical limb ischemia (CLI) and treatment of coronary artery disease in patients with acute coronary syndromes. He is involved in the development of regional and national systems of care for the treatment of CLI, ST-Elevation Myocardial Infarction (STEMI), and management of complex coronary and peripheral vascular disease. He has a well-established network of peers and associates who are viewed as key opinion leaders within the global cardiovascular community.
Dr. Adams plays an integral role in global peer education. He strives to advance the field of medicine through leadership and moderation of, as well as participation in, numerous cardiovascular and peripheral vascular forums spanning national and global platforms.
He is a sought-after speaker and well-published researcher, serving as primary investigator for multiple clinical trials. He is certified by The American Board of Internal Medicine in internal medicine and cardiovascular disease.
“It is with great honor and excitement that I join the Cordis team as Chief Medical Officer,” said Dr. Adams. “I look forward to playing a role in reinvigorating an incredible 62-year legacy. I am grateful to be a part of the future that Cordis is building with integrity and a vision for innovation.”
Source: Cordis(Press release)
